Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Shares Outstanding (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Shares Outstanding for 16 consecutive years, with $93.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.41% to $93.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.5 million through Dec 2025, up 2.41% year-over-year, with the annual reading at $93.5 million for FY2025, 2.41% up from the prior year.
  • Shares Outstanding for Q4 2025 was $93.5 million at Myriad Genetics, roughly flat from $93.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $93.5 million in Q4 2025, with the low at $76.7 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $85.4 million, with a median of $82.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding rose 1.48% in 2023, then increased 11.04% in 2024.
  • Over 5 years, Shares Outstanding stood at $80.0 million in 2021, then increased by 1.5% to $81.2 million in 2022, then grew by 10.71% to $89.9 million in 2023, then grew by 1.56% to $91.3 million in 2024, then rose by 2.41% to $93.5 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $93.5 million, $93.1 million, and $93.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.